SG Americas Securities
TCRX icon

SG Americas Securities’s TScan Therapeutics TCRX Stock Holding History

SG Americas Securities’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,581
Closed -$19K – 3577
2025
Q1 		$19K Sell
13,581
-6,834
-33% -$14.8K ﹤0.01% 3385
2024
Q4 		$62K Buy
20,415
+4,852
+31% +$22K ﹤0.01% 2864
2024
Q3 		$78K Buy
+15,563
New +$93.9K ﹤0.01% 3143

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SG Americas Securities's TCRX Position: Q2 2025 in Review

SG Americas Securities sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 13,581 shares — an estimated $19K sold.

SG Americas Securities first reported a position in TCRX in Q3 2024 and held it in 3 quarters. The position peaked at $78K in Q3 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

  • SG Americas Securities reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 13,581 TScan Therapeutics shares in Q2 2025, an estimated $19K.
  • SG Americas Securities first reported a position in TScan Therapeutics in Q3 2024 and held it in 3 quarters.
  • SG Americas Securities's TScan Therapeutics position peaked at $78K in Q3 2024.
  • 81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.